共 118 条
[1]
Aapro M(2008)Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel Ann Oncol 19 420-432
[2]
Abrahamsson PA(2003)Aetiology of bone disease and the role of bisphosphonates in multiple myeloma Lancet Oncol 4 284-292
[3]
Body JJ(2003)Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses Cancer 98 1802-1810
[4]
Ashcroft AJ(2004)Endogenous sex hormones in relation to age, sex, lifestyle factors, and chronic diseases in a general population: the Tromso study J Clin Endocrinol Metab 89 6039-6047
[5]
Davies FE(1998)Current use of bisphosphonates in oncology. International Bone and Cancer Study Group J Clin Oncol 16 3890-3899
[6]
Morgan GJ(2009)Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer 9 77-85
[7]
Baum M(2008)Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results Cancer 112 1001-1010
[8]
Buzdar A(2010)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 3784-3796
[9]
Cuzick J(2006)Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations J Natl Compr Canc Netw 4 971-979
[10]
Bjornerem A(2005)Fracture risk among breast cancer survivors: results from the Women’s Health Initiative Observational Study Arch Intern Med 165 552-558